Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

Design and construction of a new human naïve single-chain fragment variable antibody library, IORISS1.

Pasello M, Zamboni S, Mallano A, Flego M, Picci P, Cianfriglia M, Scotlandi K.

J Biotechnol. 2016 Apr 20;224:1-11. doi: 10.1016/j.jbiotec.2016.02.034. Epub 2016 Mar 2.

PMID:
26945728
2.

Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma.

Moricoli D, Carbonella DC, Dominici S, Fiori V, Balducci MC, Guerzoni C, Manara MC, Pasello M, Laguardia ME, Cianfriglia M, Scotlandi K, Magnani M.

Appl Microbiol Biotechnol. 2016 May;100(9):3949-63. doi: 10.1007/s00253-015-7226-5. Epub 2015 Dec 21.

PMID:
26685854
3.

The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitro.

Dupuis ML, Fiori V, Soriani A, Ricci B, Dominici S, Moricoli D, Ascione A, Santoni A, Magnani M, Cianfriglia M.

J Immunother. 2015 Nov-Dec;38(9):357-70. doi: 10.1097/CJI.0000000000000100.

4.

CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.

Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K.

Clin Cancer Res. 2015 Jan 1;21(1):146-56. doi: 10.1158/1078-0432.CCR-14-0492. Epub 2014 Dec 11.

5.

Blocking monocyte transmigration in in vitro system by a human antibody scFv anti-CD99. Efficient large scale purification from periplasmic inclusion bodies in E. coli expression system.

Moricoli D, Muller WA, Carbonella DC, Balducci MC, Dominici S, Watson R, Fiori V, Weber E, Cianfriglia M, Scotlandi K, Magnani M.

J Immunol Methods. 2014 Jun;408:35-45. doi: 10.1016/j.jim.2014.04.012. Epub 2014 May 4.

6.

Isolation of a new human scFv antibody recognizing a cell surface binding site to CEACAM1. Large yield production, purification and characterization in E. coli expression system.

Moricoli D, Laguardia ME, Carbonella DC, Balducci MC, Dominici S, Fiori V, Serafini G, Flego M, Cianfriglia M, Magnani M.

Protein Expr Purif. 2014 Jan;93:38-45. doi: 10.1016/j.pep.2013.10.009. Epub 2013 Oct 30.

PMID:
24184403
7.

Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.

Dupuis ML, Ascione A, Palmisano L, Vella S, Cianfriglia M.

BMC Pharmacol Toxicol. 2013 Sep 20;14:47. doi: 10.1186/2050-6511-14-47.

8.

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML).

Cianfriglia M.

Ann Ist Super Sanita. 2013;49(2):190-208. doi: DOI: 10.4415/ANN_13_02_11. Review.

9.
10.

Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.

Flego M, Ascione A, Cianfriglia M, Vella S.

BMC Med. 2013 Jan 4;11:4. doi: 10.1186/1741-7015-11-4. Review.

11.

The expression and modulation of CEACAM1 and tumor cell transformation.

Fiori V, Magnani M, Cianfriglia M.

Ann Ist Super Sanita. 2012;48(2):161-71. doi: DOI: 10.4415/ANN_12_02_09. Review.

12.

Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells.

Gellini M, Ascione A, Flego M, Mallano A, Dupuis ML, Zamboni S, Terrinoni M, D'Alessio V, Manara MC, Scotlandi K, Picci P, Cianfriglia M.

Curr Pharm Biotechnol. 2013;14(4):449-63.

PMID:
22335486
13.

P-glycoprotein binds to ezrin at amino acid residues 149-242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma.

Brambilla D, Zamboni S, Federici C, Lugini L, Lozupone F, De Milito A, Cecchetti S, Cianfriglia M, Fais S.

Int J Cancer. 2012 Jun 15;130(12):2824-34. doi: 10.1002/ijc.26285. Epub 2011 Oct 20.

14.

The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.

Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, Cianfriglia M, Testa U.

Blood Cells Mol Dis. 2010 Jun 15;45(1):86-92. doi: 10.1016/j.bcmd.2010.03.008. Epub 2010 May 4.

PMID:
20444629
16.

Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1.

Ascione A, Capecchi B, Campitelli L, Imperiale V, Flego M, Zamboni S, Gellini M, Alberini I, Pittiglio E, Donatelli I, Temperton NJ, Cianfriglia M.

Antiviral Res. 2009 Sep;83(3):238-44. doi: 10.1016/j.antiviral.2009.05.005. Epub 2009 May 27.

PMID:
19481117
17.

The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.

Ascione A, Cianfriglia M, Dupuis ML, Mallano A, Sau A, Pellizzari Tregno F, Pezzola S, Caccuri AM.

Cancer Chemother Pharmacol. 2009 Jul;64(2):419-24. doi: 10.1007/s00280-009-0960-6. Epub 2009 Mar 15.

PMID:
19288261
18.

Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates.

Viale M, Cordazzo C, Cosimelli B, de Totero D, Castagnola P, Aiello C, Severi E, Petrillo G, Cianfriglia M, Spinelli D.

J Med Chem. 2009 Jan 22;52(2):259-66. doi: 10.1021/jm801195k.

PMID:
19093883
19.

Generation and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from yeast.

Mallano A, Zamboni S, Carpinelli G, Santoro F, Flego M, Ascione A, Gellini M, Tombesi M, Podo F, Cianfriglia M.

BMC Biotechnol. 2008 Sep 10;8:68. doi: 10.1186/1472-6750-8-68.

20.

Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast.

Zamboni S, Mallano A, Flego M, Ascione A, Dupuis ML, Gellini M, Barca S, Cianfriglia M.

Int J Oncol. 2008 Jun;32(6):1245-51.

PMID:
18497986

Supplemental Content

Loading ...
Support Center